Email this Page
Print this Page 
E3108 - A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
GCC 0107 - Determination of the Level of Circulating PC-Cell Derived Growth Factor (PCDGF) in Breast Cancer Patients
GCC 0723 - DRIT: A Prospective Correlative Drug Response Indicator (DRI) Tissue Analysis Study for Stage 3 and 4 Breast Cancer Patients
GCC 0845 - A PILOT AND PHASE II STUDY OF VORINOSTAT AND LAPATINIB IN WOMEN WITH LOCAL RECURRENT OR METASTATIC BREAST CANCER TO EVALUATE RESPONSE AND SURROGATE BIOMARKERS OF EPITHELIAL-MESENCHYMAL TRANSITION AND BREAST CANCER STEM CELLS
GCC 0901 - PHASE II STUDY OF EVEROLIMUS, LAPATINIB, AND LETROZOLE IN POSTMENOPAUSAL WOMEN WITH ADVANCED ENDOCRINE RESISTANT BREAST CANCER
GCC 0902 - A Feasibility Study to Identify Microtentacles and Stem Cell Phenotype of Circulating Cancer Cells in Locally Advanced or Metastatic Breast Cancer
GCC 0919 - PRE-OPERATIVE ACCELERATED PARTIAL BREAST IRRADIATION (APBI) FOR WOMEN WITH STAGE I AND SELECT IIA BREAST CANCER
GCC 0927 - A PILOT AND PHASE II STUDY OF ENTINOSTAT AND ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH OPERABLE TRIPLE NEGATIVE BREAST CANCER TO EVALUATE BIOMARKERS AND SURROGATES FOR RESPONSE
GCC 0930 - A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors
GCC 1015 - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
GCC 1057 - Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
GCC 1131 - GCC 1131: LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment
GCC 1162 - GCC 1162: BIG 4-11 / BO25126 / TOC4939g (APHINITY): A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer
GCC 1167 - GCC1167- A PILOT PROSPECTIVE CASE CONTROL STUDY OF AROMATASE INHIBITOR-ASSOCIATED MUSCULOSKELETAL SYMPTOMS (AIMSS) AND AUDIOLOGIC ABNORMALITIES IN BREAST CANCER PATIENTS TAKING AROMATASE INHIBITORS
GCC 1211 - 064-00 A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
MA.32 - A PHASE III RANDOMIZED TRIAL OF METFORMIN VERSUS PLACEBO ON RECURRENCE AND SURVIVAL IN EARLY STAGE BREAST CANCER
NSABP-B47 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
RTOG 0413 - NSABP PROTOCOL B-39 : A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer.
RTOG 1014 HP-00047251 - A PHASE II STUDY OF REPEAT BREAST PRESERVING SURGERY AND 3D-CONFORMAL PARTIAL BREAST RE-IRRADIATION (PBrl) FOR LOCAL RECURRENCE OF BREAST CARCINOMA
|
Email this Page
Print this Page
|
